Alex Philippidis on Muck Rack

Alex Philippidis

Verified
White Plains
As seen in: Gen, Genetic Engineering & Biotechnology News, SAGE Publishing, Flipboard, Mary Ann Liebert, Inc., EIN News, Genetic Literacy Project, NewsBreak, Inside Precision Medicine
Senior Business Editor, Genetic Engineering & Biotechnology News, GEN Edge, and Mary Ann Liebert Inc., New Rochelle, NY. genengnews.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Alex

Contact Alex, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

California Still Golden Despite Job Losses: Industry Group

|
By Alex Philippidis Verified
| Genetic Engineering & Biotechnology News Verified
Home Topics Translational Medicine California Still Golden Despite Job Losses: Industry Group Carter Jaynes, radioligand therapy (RLT) production manager at Novartis, at work in the company’s *10,000-square-foot radioligand therapy (RLT) manufacturing facility for cancer treatments in Carlsbad, CA, which opened last November as the pharma giant’s third U.S.-based RLT site. Novartis says Jaynes was inspired to pursue a role in healthcare as a result of his mother’s journey with cancer.
Open in Who Shared View Duplicates (2) Issue with article?

Gene Editing Pioneer Sangamo Files for Chapter 11 Bankruptcy; Agrees to Sell Assets

|
By Kevin Davies Verified, Alex Philippidis Verified
| Genetic Engineering & Biotechnology News Verified
Home Topics Genome Editing Gene Editing Pioneer Sangamo Files for Chapter 11 Bankruptcy; Agrees to Sell... Researchers at work in Sangamo Therapeutics' laboratory. The pioneer gene editing biotech company has filed for Chapter 11 bankruptcy protection, and has agreed to sell some of its programs and platforms to Eli Lilly and Astellas, in deals subject to placing the winning bids at a future bankruptcy court auction.
Open in Who Shared View Duplicates (2) Issue with article?

AbbVie to Acquire Apogee Therapeutics for $10.9B

|
By Alex Philippidis Verified
| Genetic Engineering & Biotechnology News Verified
Home Topics Translational Medicine AbbVie to Acquire Apogee Therapeutics for $10.9B Two AbbVie researchers at work. AbbVie has agreed to acquire Apogee Therapeutics for $10.9 billion, in a deal designed to bolster the buyer’s pipeline with an atopic dermatitis (AD) candidate set to advance to Phase III trials during the second half of this year, and being positioned as a potential challenger to a top-selling drug.
Open in Who Shared View Duplicates (2) Issue with article?
See all 3,221 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified